Abacus Life, Inc. (NASDAQ:ABL - Free Report) - Equities researchers at B. Riley issued their Q1 2025 earnings per share (EPS) estimates for shares of Abacus Life in a report issued on Monday, November 25th. B. Riley analyst M. Howlett anticipates that the company will post earnings of $0.25 per share for the quarter. B. Riley has a "Buy" rating and a $17.00 price objective on the stock. The consensus estimate for Abacus Life's current full-year earnings is $0.64 per share. B. Riley also issued estimates for Abacus Life's Q2 2025 earnings at $0.26 EPS, Q3 2025 earnings at $0.27 EPS, Q4 2025 earnings at $0.27 EPS, FY2025 earnings at $1.05 EPS, Q1 2026 earnings at $0.36 EPS, Q2 2026 earnings at $0.38 EPS, Q3 2026 earnings at $0.40 EPS and FY2026 earnings at $1.56 EPS.
Abacus Life (NASDAQ:ABL - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.14 by $0.06. The business had revenue of $28.15 million for the quarter, compared to analysts' expectations of $26.08 million. Abacus Life had a positive return on equity of 12.88% and a negative net margin of 11.65%. During the same period in the previous year, the business posted $0.01 earnings per share.
A number of other analysts have also recently weighed in on ABL. B. Riley Financial reiterated a "buy" rating and issued a $16.00 price target on shares of Abacus Life in a research report on Friday, August 30th. TD Cowen assumed coverage on Abacus Life in a research note on Wednesday, August 7th. They issued a "buy" rating and a $14.00 price objective on the stock. Northland Securities assumed coverage on Abacus Life in a research note on Thursday, October 24th. They issued an "outperform" rating and a $13.50 price objective on the stock. Northland Capmk raised Abacus Life to a "strong-buy" rating in a research note on Thursday, October 24th. Finally, Piper Sandler reissued an "overweight" rating and issued a $13.00 price objective (up previously from $12.00) on shares of Abacus Life in a research note on Friday, November 8th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Abacus Life presently has an average rating of "Buy" and an average price target of $14.70.
Check Out Our Latest Stock Analysis on Abacus Life
Abacus Life Stock Performance
Shares of ABL traded up $0.26 on Wednesday, reaching $8.08. 489,376 shares of the stock traded hands, compared to its average volume of 82,572. The stock's 50-day moving average price is $9.22 and its 200-day moving average price is $9.75. Abacus Life has a 12 month low of $6.56 and a 12 month high of $13.25. The firm has a market cap of $603.17 million, a price-to-earnings ratio of -43.44 and a beta of 0.15. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.29 and a quick ratio of 1.29.
Insider Buying and Selling at Abacus Life
In other Abacus Life news, CEO Jay J. Jackson sold 2,031,250 shares of the stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $8.00, for a total value of $16,250,000.00. Following the completion of the sale, the chief executive officer now directly owns 10,562,000 shares in the company, valued at $84,496,000. This represents a 16.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Adam Samuel Gusky purchased 18,241 shares of the stock in a transaction on Friday, November 22nd. The stock was acquired at an average price of $7.54 per share, with a total value of $137,537.14. Following the completion of the acquisition, the director now directly owns 40,959 shares of the company's stock, valued at approximately $308,830.86. This represents a 80.29 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 79.20% of the company's stock.
Institutional Investors Weigh In On Abacus Life
Several large investors have recently modified their holdings of ABL. Renaissance Technologies LLC bought a new position in shares of Abacus Life during the second quarter worth about $106,000. Levin Capital Strategies L.P. bought a new position in shares of Abacus Life during the second quarter worth about $130,000. Richard W. Paul & Associates LLC grew its holdings in shares of Abacus Life by 4.8% during the second quarter. Richard W. Paul & Associates LLC now owns 30,448 shares of the company's stock worth $263,000 after buying an additional 1,401 shares in the last quarter. Quarry LP bought a new position in shares of Abacus Life during the second quarter worth about $318,000. Finally, Sei Investments Co. bought a new position in shares of Abacus Life during the second quarter worth about $418,000.
Abacus Life Company Profile
(
Get Free Report)
Abacus Life, Inc operates as an alternative asset manager specializing in life insurance products. It purchases life insurance policies from consumers seeking liquidity and manages policies over time via trading, holding, and/or servicing. The company was founded in 2004 and is based in Orlando, Florida.
Featured Stories
Before you consider Abacus Life, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abacus Life wasn't on the list.
While Abacus Life currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
